Form 4: Guardant Health CEO Reports Stock Transaction
Insider Transaction (Form 4)
Helmy Eltoukhy, Co-Chief Executive Officer and a Director of Guardant Health, Inc., reported multiple transactions in common stock on September 30, 2026.
Summary
- Option exercise/conversion: acquired 2,817 Common Stock on September 30, 2026; holds 1,943,751 after (Indirect).
- Tax/exercise-price withholding: disposed of 1,428 Common Stock at $178.36 ($254,698) on September 30, 2026; holds 1,942,323 after (Indirect).
- Option exercise/conversion: acquired 23,997 Common Stock on October 1, 2026; holds 1,966,320 after (Indirect).
- Option exercise/conversion: acquired 9,716 Common Stock on October 1, 2026; holds 1,976,036 after (Indirect).
- Tax/exercise-price withholding: disposed of 17,087 Common Stock at $174.75 ($2,985,953) on October 1, 2026; holds 1,958,949 after (Indirect).
- Option exercise/conversion: disposed of 2,817 Restricted Stock Units on September 30, 2026; holds 2,817 after (Direct).
- Option exercise/conversion: disposed of 23,997 Restricted Stock Units on October 1, 2026; holds 23,998 after (Direct).
- Option exercise/conversion: disposed of 9,716 Restricted Stock Units on October 1, 2026; holds 48,580 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Helmy Eltoukhy — Director, Officer (Co-Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Option exercise/conversion | Common Stock | 2,817 | — | — | 1,943,751 |
| 2026-09-30 | Tax/exercise-price withholding | Common Stock | 1,428 | $178 | $254.7K | 1,942,323 |
| 2026-10-01 | Option exercise/conversion | Common Stock | 23,997 | — | — | 1,966,320 |
| 2026-10-01 | Option exercise/conversion | Common Stock | 9,716 | — | — | 1,976,036 |
| 2026-10-01 | Tax/exercise-price withholding | Common Stock | 17,087 | $175 | $3.0M | 1,958,949 |
| 2026-09-30 | Option exercise/conversion | Restricted Stock Units | 2,817 | — | — | 2,817 |
| 2026-10-01 | Option exercise/conversion | Restricted Stock Units | 23,997 | — | — | 23,998 |
| 2026-10-01 | Option exercise/conversion | Restricted Stock Units | 9,716 | — | — | 48,580 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Option exercise/conversion (2,817 shares) |
| 2026-09-30 | Tax/exercise-price withholding (1,428 shares) |
| 2026-10-01 | Option exercise/conversion (23,997 shares) |
| 2026-10-01 | Option exercise/conversion (9,716 shares) |
| 2026-10-01 | Tax/exercise-price withholding (17,087 shares) |
| 2026-09-30 | Option exercise/conversion (2,817 shares) |
| 2026-10-01 | Option exercise/conversion (23,997 shares) |
| 2026-10-01 | Option exercise/conversion (9,716 shares) |
Keywords
insider transaction, Form 4, GH, Guardant Health, Inc., neutral, Helmy Eltoukhy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.